As a snarl of pharma-focused lawsuits from Texas Attorney General Ken Paxton play out, Gilead Sciences has worked out a deal ...

The U.S. Treasury Department is closing in on American investments in China's life sciences industry as it issued draft rules ...

Yesterday, argenx's stock slipped by more than 2%—with its shares still down slightly as of Friday morning—after the Dutch ...

In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact ...

Pfizer’s newest round of workforce cuts may be getting an early start.  | Local news reported Pfizer layoffs in Michigan and ...

After disappointing Wall Street for most of 2026, Roche’s eye disease drug Vabysmo met analysts’ expectations for the first ...

With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

This week, the companies announced wins across their late-stage Clarity-1 and Clarity-2 studies of once-daily brepocitinib in ...

The FDA rebuked Baxter in a lengthy warning letter that outlined a series of production violations that led to a trio of ...

Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling ...